Literature DB >> 9888836

Desazadesmethyldesferrithiocin analogues as orally effective iron chelators.

R J Bergeron1, J Wiegand, W R Weimar, J R Vinson, J Bussenius, G W Yao, J S McManis.   

Abstract

Further structure-activity studies of desferrithiocin analogues are carried out. (S)-Desazadesmethyldesferrithiocin, 2-(2-hydroxyphenyl)-Delta2-thiazoline-4(S)-carboxylic acid, serves as the principal framework in the current paper. Desazadesmethyldesferrithiocin can be structurally altered with facility, and data are already available on its iron-clearing properties and toxicity parameters. Four different kinds of structural modifications of this framework are undertaken: introduction of hydroxy, carboxy, or methoxy groups on the aromatic ring; alteration of the thiazoline ring; increasing the distance between the ligand donor atoms; and benz-fusion of the aromatic rings. The structural modifications described are shown to have a tremendous impact on both the iron clearance and toxicity profiles of the desazadesmethyldesferrithiocin molecule. All of the compounds are assessed in a bile-duct-cannulated rodent model to determine iron clearance efficiency. Ligands which demonstrate an efficiency of greater than 2% are carried forward to the iron-overloaded primate for iron-clearing measurements. Ligands with efficiencies greater than 3% in the primate are then evaluated in a formal toxicity study in rodents. On the basis of the results of the present work, 2-(2, 4-dihydroxyphenyl)-Delta2-thiazoline-4(S)-carboxylic acid is a promising candidate for clinical evaluation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9888836     DOI: 10.1021/jm980340j

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

1.  The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues.

Authors:  Raymond J Bergeron; Neelam Bharti; Jan Wiegand; James S McManis; Shailendra Singh; Khalil A Abboud
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

2.  The design, synthesis, and evaluation of organ-specific iron chelators.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; Neelam Bharti
Journal:  J Med Chem       Date:  2006-11-30       Impact factor: 7.446

3.  Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma.

Authors:  Jianjun Chen; Zhao Wang; Yan Lu; James T Dalton; Duane D Miller; Wei Li
Journal:  Bioorg Med Chem Lett       Date:  2008-05-01       Impact factor: 2.823

4.  Desferrithiocin is a more potent antineoplastic agent than desferrioxamine.

Authors:  Anthony Kicic; Anita C G Chua; Erica Baker
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

5.  (S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; John R T Vinson; Hua Yao; Neelam Bharti; James R Rocca
Journal:  J Med Chem       Date:  2006-05-04       Impact factor: 7.446

6.  Synthesis of nonproteinogenic amino acids to probe lantibiotic biosynthesis.

Authors:  Xingang Zhang; Weijuan Ni; Wilfred A van der Donk
Journal:  J Org Chem       Date:  2005-08-19       Impact factor: 4.354

7.  Prevention of acetic acid-induced colitis by desferrithiocin analogs in a rat model.

Authors:  Raymond J Bergeron; Jan Wiegand; William R Weimar; John Nhut Nguyen; Charles A Sninsky
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

8.  Desferrithiocin analogues and nephrotoxicity.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; Neelam Bharti; Shailendra Singh
Journal:  J Med Chem       Date:  2008-09-13       Impact factor: 7.446

9.  Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.

Authors:  Raymond J Bergeron; Jan Wiegand; Neelam Bharti; James S McManis
Journal:  J Med Chem       Date:  2012-08-13       Impact factor: 7.446

10.  Desferrithiocin analogue uranium decorporation agents.

Authors:  Raymond J Bergeron; Jan Wiegand; Shailendra Singh
Journal:  Int J Radiat Biol       Date:  2009-04       Impact factor: 2.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.